Retatrutide is getting a lot of attention. But what does the research actually show?
Triple agonist. GLP-1 + GIP + glucagon receptor activity. Major weight-loss results in clinical trials—and still investigational.
@ajpakpour.bsky.social@ajpakpour.bsky.social